Analyst firms · Morgan Stanley · SAGE
Morgan Stanley SAGE price target and rating history
Sage Therapeutics Inc. (SAGE) · Health Care
Morgan Stanley rates Sage Therapeutics Inc. (SAGE) Equal-Weight with a $57 price target, as of its latest action on Mar 10, 2022. It has published 3 rating actions on SAGE since October 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Equal-Weight
- Price target
- $57
- Median target, all firms
- Too few
- Actions on SAGE
- 3
Morgan Stanley price target on SAGE
Every Morgan Stanley rating on SAGE
- Mar 10, 2022
- Oct 19, 2021
- Oct 12, 2021
Questions about Morgan Stanley and SAGE
- What is Morgan Stanley's price target for SAGE?
- Morgan Stanley's latest stated price target for Sage Therapeutics Inc. (SAGE) is $57, from its action on Mar 10, 2022.
- What is Morgan Stanley's rating on SAGE?
- Morgan Stanley rates SAGE Equal-Weight, a neutral rating, as of Mar 10, 2022.
- When did Morgan Stanley last change its view on SAGE?
- On Mar 10, 2022, Morgan Stanley cuts its price target to $57 from $61, keeps Equal-Weight.
More SAGE rating histories
All Morgan Stanley ratingsSAGE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.